Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorised
June 11, 2020

Clinical trial disruption due to Covid-19 has begun to slow

By Miranda Mclaren

Since early March, many companies have delayed the initiation of or completely withdrawn planned clinical trials, as well as suspending enrolment in or terminating ongoing trials.  The majority of the disruption, at 61.5%, was due to the suspension of enrolment. Trials currently being impacted due to slow enrolment follows at 22.8%, then finally, 15.7% of trials have delayed initiation. Within the 22.8% of trials affected by slow enrolment, 12.5% of these are specifically due to the availability of sites and investigators.

Tracking these disrupted trials with the Covid-19 dashboard on the Pharma Intelligence Center, GlobalData has found that the number of disrupted trials has begun to slow. Over all three months, the majority of disrupted clinical trials were in Phase II, from 43–45%, followed by Phase III with 22–25%, Phase I with 21–26%, and Phase IV with 7–10%.

To read more, please click here.

Related Companies

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU